Skip Navigation



NDT Advance Access published online on August 7, 2009

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp393
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kane, G. C.
Right arrow Articles by Garovic, V. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kane, G. C.
Right arrow Articles by Garovic, V. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis

Garvan C. Kane1, Nancy Xu2, Erik Mistrik3, Tomas Roubicek3, Anthony W. Stanson4 and Vesna D. Garovic2

1 Division of Cardiovascular Diseases 2 Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA 3 Charles University, Hradec Karlove, Czech Republic 4 Department of Radiology, Mayo Clinic, Rochester, MN, USA

Correspondence and offprint requests to: Vesna D. Garovic; E-mail: garovic.vesna{at}mayo.edu



  Abstract

Background. Renal artery stenosis (RAS) impacts the pathogenesis and control of heart failure (HF) and may further contribute to increased cardiovascular morbidity and mortality in HF patients. However, the long-term effects of renal artery revascularization on cardiovascular outcomes in HF patients are not well studied.

Methods. The prevalence of HF and its effects on all-cause mortality were studied in 163 consecutive patients with systemic hypertension and chronic kidney disease (serum creatinine >2 mg/dL) who underwent percutaneous transluminal renal angioplasty (PTRA) with stenting for atherosclerotic RAS. In addition, in 100 patients with RAS and coexistent HF, we compared the impact of medical treatment (n = 50) versus PTRA (n = 50) on clinical outcomes.

Results. HF (predominantly normal ejection fraction) was present in 50/163 (31%) patients with systemic hypertension and chronic kidney disease (serum creatinine >2 mg/ dL) undergoing PTRA for RAS and represented the major predictor of all-cause mortality in these patients. When compared with sex-matched RAS and HF patients treated medically, PTRA with stenting was associated with a significant decrease in the New York Heart Association Functional Class (1.9 ± 0.8 versus 2.6 ± 1.0, P < 0.04) and a 5-fold reduction in the number of hospitalizations. However, renal artery revascularization did not impact mortality.

Conclusion. HF was present in one-third of patients with renal dysfunction and atherosclerotic RAS who were referred for PTRA. The presence of HF was associated with a significantly increased risk of death after PTRA with stenting. Renal artery revascularization resulted in improved HF control and a reduction in HF hospitalizations.

Keywords: heart failure (HF); hypertension; percutaneous transluminal renal angioplasty (PTRA); pulmonary oedema; renal artery stenosis (RAS)

Received for publication: 17. 5.09
Accepted in revised form: 13. 7.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.